Curriculum Vitae
Thomas J. Smith, M.D., F.A.C.P.
1 Personal Information
1.1 Name: Thomas J. Smith, M.D., F.A.C.P.
1.2 Born Cuyahoga Falls, Ohio, U.S.A. September 19, 1952
1.3 Citizenship: USA
1.4 Marital Status: Married, Joann Norma Bodurtha, M.D., MPH; Associate Professor of Human Genetics, Pediatrics, and Obstetrics/Gynecology
1.4.1 Children: Anna Jo Bodurtha Smith, born July 14, 1988
1.5 Home Address: 14219 Hickory Oaks Lane, Ashland, Virginia 23005,
(804)-798-5730
1.6 Business Address: Medical College of Virginia at Virginia Commonwealth University, Division of Hematology, 1101 East Marshall Street, PO Box 980230, Richmond, VA 23298-0230. E mail
2 Licensure
2.1.1 Virginia 0101037893
2.1.2 DEA AS2593312
2.1.3 NCI Investigator No. 09961
2.1.4 ACLS Provider April 2001-3
2.2 Board Certification
2.3 ELNEC Certification, July 24-27, 2007
2.4 Hospice and Palliative Care Medicine, February 2003-2013.
2.5 Advanced Cardiac Life Support Provider Renewal, Center for Trauma and Critical Care, April 7, 2001
2.6 Hematology, 1990-2000
2.7 Medical Oncology, 1987-
2.8 Internal Medicine, 1982-
3 Education
3.1 Medical College of Virginia-Virginia Commonwealth University Fellowship in Hematology/Oncology 1982- 1987, Board certified in 1987; 1990.
3.2 Special Visiting Fellow, National Cancer Center Biological Response Modifiers Program, Frederick, MD 1986
3.3 Yale University School of Medicine, M.D. cum laude 1974-79
3.4 Yale University School of Organization and Management (core curriculum)1977-78
3.5 University of Akron, B.S., summa cum laude 1971-74
3.6 Ohio Governor's School, Fellowship in Management 1971
4 Military Service Record: None
5 Postdoctoral Training
5.1 Faculty Scholar, Program on Death in America, Open Society, New York 1995-9
5.2 Special Fellow in Medical Oncology, National Cancer Institute, NCI-BRMP, Frederick, MD 1986
2
5.2.1 Fellow in Hematology/Oncology, Medical College of Virginia, Richmond, VA 1984-89
5.2.2 Residency in Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1979-82
6 Academic Appointments or Other Significant Work Experience
6.1 2002- Esteemed Professor of Medicine (oncology), VCU
6.2 2001-5 Institute of Medicine National Cancer Policy Board
6.3 1999- Chair, Division of Hematology/Oncology
6.4 1999- Clinical Oncology Services Committee, MCVH
6.5 1999- Professor, Medicine and Health Administration
6.6 1999- Medical Director, Thomas Hospice Palliative Care Unit, MCVH
6.7 1998 Clinical Practice Guidelines Committee Panel, MCVH
6.8 1998- Advisory Board, Thomas Hospice/Palliative Care Unit at MCVH
6.9 1997- Group Leader, Albert Schweitzer Institute for the Humanities, Continuing Medical Education in Kyrgyzstan
6.10 1997- MCVH Hospice Working Group Leader
6.11 1995-9 Associate Professor of Medicine and Health Administration
6.12 1995- Physician, Cross-Over Health Ministry, Richmond, Virginia
6.13 1995-8 Chairman, American Society of Clinical Oncology Health Service Research Committee; $250,000 annual budget.
6.14 1995-7 Vice-Chair, Cancer and Leukemia Group B Economics and Outcomes Research Subcommittee
6.15 1994-7 MCV Hospitals/Mercer Management Corporation Re-engineering Project. Charged with reducing oncology pharmacy costs by 20% in 3 years
6.16 1992- Director of Cancer Education, Massey Cancer Center
6.17 1992- Associate Member, Williamson Institute of Health Economics
6.18 1990- Assistant Professor of Medicine & Health Administration
7 Membership - Scientific, Honorary and Professional Societies
7.1 Member, ASCO Cost of Cancer Care Task Force, August 2007-
7.2 Member, ASCPRO “Assessing the symptoms of cancer using patient related outcomes” Advisory Panel to the FDA, Charles Cleeland, PI
7.3 National Cancer Institute of Canada's Health Economics, Services, Policy, and Ethics (HESPE) Cancer Research Centre Planning Committee, April 2007-
7.4 ASCO Quality Oncology Practice Initiative Best Practices Work Group 2006-
7.5 Reviewer, Belgian Cancer Society, 2006-
7.6 RAND Technical Panel, Quality Measures at end of life, Karl Lorenz, PI, 2006-
7.7 MGH-Partners Technical Advisory Panel for End of Life benchmarks, Jennifer Hass MD, PI, 2006-
7.8 Chair, American Society of Clinical Oncology Expert Panel, White Cell Growth Factors, 2005-6.
7.9 Member, American Society of Clinical Oncology Expert Panel, Breast Cancer Surveillance, 2005-6.
7.10 Chair, National Quality Forum Project on Hospital Guidelines for Symptom Management and End of Life Care, 2004-.
7.11 National Consensus Project Advisory Council Project on Quality Palliative Care: Essential Elements and Best Practices 2002-4
7.12 External Reviewer, NCI CanCORS cancer surveillance program, 2002-6
7.13 American Society of Clinical Oncology Program Committee 2001-3
7.14 National Marrow Donor Program Optimal Size Registry Analysis Expert Panel 2000-5
7.15 American Cancer Society Grant Review Committee 2001-5
7.16 American Society of Clinical Oncology
7.16.1 Member (with RAND, Komen Foundation, Harvard School of Public Health) National Initiative on Cancer Care Quality 1999-
7.16.2 Chairman, Committee on Health Service Research 1994-98
7.16.3 Committee for Health Service Research - 1999-01
7.17 Board of Editors, Journal of Clinical Oncology - 1995-98
7.18 Co-chair, Guidelines Review Panel on use of hematopoeitic growth factors - 1998-00
7.19 Director, ASCO Curriculum on Palliative Care, 1999-
7.20 Member, ASCO Working Group on Guidelines Evaluation
7.21 Member, Expert Panel on Use of Tamoxifen/Raloxifene for Breast Cancer Prevention 1999
7.22 Member, Task Force on Improving Care at the End of Life
7.23 Member, Task Force on Managed Care
7.24 Member, Expert Panel to Determine Outcomes that Justify Cancer Treatment
7.25 Member, Expert Panel on Hematopoietic Growth Factors
7.26 Member, Expert Panel on Non Small Cell Lung Cancer Treat
7.27 Member, Expert Panel on Breast Cancer follow up care
7.28 Member, Expert Panel on Colorectal Cancer follow up care
7.29 Member, Expert Panel on Tumor Markers
7.30 Member, Expert Panel on Unresectable Prostate Cancer Care
7.31 Editor, Colorectal Cancer Follow up Care Guidelines
7.32 American Medical Association
7.33 Fellow, American College of Physicians
7.34 American Association for the Advancement of Science
7.35 Virginia Society of Hematology/Oncology, President, 1989-90
7.36 Virginia Hematology/Oncology Association 1994-
7.37 American Association for Cancer Education 1986-92
7.38 Cancer and Leukemia Group B
7.39 Vice-Chairman, Economics Committee - 1997 -2000
7.40 Liason, Leukemia Committee - 1998-01
7.41 National Surgical Adjuvant Breast and Bowel Cancer Program
7.42 American Society for Blood and Marrow Transplantation
7.43 European Society for Medical Oncology 1998-
7.44 Multinational Association for the Study of Supportive Care in Cancer
8 Membership in Community Organizations
8.1 2007- Member, Chris Desch Foundation Board
8.2 2004- Ashland Friends of the Library Board
8.3 2000- Salvation Army Boys and Girls Clubs Camp Happyland summer camp physicals
8.4 1995-99 Board of Directors, American Cancer Society, Hanover County Unit
8.5 1994- Physician, Cross-Over Free Health Clinic, Richmond, VA
8.6 1994- Director of Cancer Palliative Care Programs, American Medical Teams for Africa, World Health Organization/American Medical Teams for Africa Cancer Pain Relief Programme, Tanzania-Zanzibar
8.7 1991-2 Childrens Story Hour Reader, Pamunkey Regional Library, Hanover County
8.8 1985-7 Co-coordinator, Ashland Mountain of Trash (community cleanup and recycling)
8.9 1984- Richmond Friends Meeting, Richmond, VA
9 Special Awards, Fellowships, and Other Honors
9.1 Oncology Nursing Society Grant to teach End of Life Care Nursing Education Consortium (ELNEC) course, Dar es Salaam, Tanzania July 2007
9.2 ASCO IDEA Mentor for Developing Countries, Dr. Sani Malani, Nigeria, June 2007
9.3 ASCO Annual Prostate Cancer Meeting Special Lecture: “Can we afford our progress?” February 24, 2007
9.4 Co-Chair, Supportive Care Congress, NYC February 23-5, 2007
9.5 MacMillan Fund UK Plenary Lecturer: NCRI Annual Conference, Birmingham, UK October 7, 2006.
9.6 Dutch Cancer Society External Grant Reviewer, 2006.
9.7 Chair, ASCO Annual Meeting, Clinical Problems in Oncology Session “Getting savvy with opioids to manage cancer pain: routes, rotations, interventions.” June 2006
9.8 Project ASSIST, RAND Corporation, 2006-
9.9 Project DeCIDE, Technical Advisory Panel for End-of-Life Benchmarks, MGH-Partners, 2006-
9.10 VCU Outstanding Teacher Award, Hematology/Oncology M-2 course, August 2006
9.11 Jonathon Gold “Humanism in Medicine” Charter Club, 2006
9.12 International Association of Hospice and Palliative Care University Award to best university based palliative care program 2006
9.13 Faculty Award for Distinguished Clinical Care, VCU Medical Center Department of Medicine 2006
9.14 American Hospital Association “Circle of Life” award to best hospital based palliative care program
9.15 Master Trainer, EPEC-O for oncologists 2005-
9.16 Top Doctors in America: Oncology 2001-7
9.17 “Top doctors in Richmond: Oncology” Richmond Magazine, Richmond Academy of Medicine 2001-6
9.18 “America’s Top Doctors: Medical Oncology,” Castle Connelly 2001-7
9.19 Outstanding Teacher Certificate, M-II course, 2002-3, awarded October 2003.
9.20 John Eric Olson MD Visiting Lecturer and Professor, Bassett Health Care Cancer Center, Cooperstown, New York, April 17-8, 2003
9.21 Dale O. Ham MD Visiting Professor, Case Western Reserve University Ireland Cancer Center, Cleveland Ohio February 7, 2003
9.22 Alpha Omega Alpha Medical Honor Society, Brown Sequard Chapter, May 2002.
9.23 “National Top Breast Cancer Doctors” Redbook Magazine, September 2001.
9.24 Salvation Army Boys and Girls Clubs Community Outreach Award, 2001
9.25 Best Doctors in Richmond: “Top medical specialists for women: breast cancer, breast diseases” Richmond Magazine, 2001
9.26 MCV-VCU “Distinguished Clinician Award” as the outstanding clinician in practice at the medical center. May 13, 2000
9.27 Best Doctors in Richmond, “Oncology”, Richmond Magazine 2000
9.28 National “Humanism in Medicine Award” for “embodying compassion and sensitivity in the delivery of care to patients and their family members.” May 13, 2000. New Jersey Health Care Foundation.
9.29 “Pioneer in Palliative Care” program designee, Robert Wood Johnson Foundation and Milbank Memorial Fund, 2000-2001.
9.30 Best Physicians in Richmond, Virginia (Oncology), Richmond Magazine, 1999
9.30.1 Jessie Ball duPont Fund Making a Difference Award for “creation of a program which meets a critical societal need” (Rural Cancer Outreach Program) 1996
9.30.2 Sharon H. Kohlenberg Health care Service Award, for “commitment to the fight against breast cancer”, Virginia Breast Cancer Foundation, 1995
9.30.3 Scholarship Award in Patient-Physician Communications, Department of Human Genetics, Medical College of Virginia (used patent royalties to create this endowment)
9.30.4 Fellow, American College of Physicians, 1992
9.30.5 Outstanding Alumni, Chippewa Local High School, Doylestown, Ohio, 1992
9.30.6 Outstanding Paper (Dr. Bruce Hillner, coauthor), Society of Medical Decision-Making, 1991
9.30.7 Best Teacher, Department of Internal Medicine, 1989.
9.31 Fellowships
9.31.1 Visiting Professor in Palliative Care and Oncology, McGill University/University of Montreal/ Institute for Clinical Research, Montreal, Quebec, Canada, November 1998
9.31.2 Pfizer Traveling Fellowship Award, Clinical Research Institute of Montreal, Montreal, P.Q. March 1996
9.32 External Grants
9.32.1 NLM GO8 (RO1) Smith T (PI), with Khatcheressian J, Lyckholm L, Matsuyama R; consultants Crawford J, Siminoff L, Schrag D, Loprinzi C, Tannock I. Provision of honest, accurate helpful information on the Internet for patients about prognosis, treatment efficacy, and treatment decisions of breast, colorectal, lung, and prostate cancer. Goal: improve cancer treatment decisions in cancer patients by provision of honest information about prognosis, treatment options, treatment efficacy and side effects. Role: PI. 20% effort and salary
9.32.2 R01CA116227-01 (Meier). Morrison S, Meier D, Smith T, et al. (9/29/06 approved for funding ; 5 years) Impact of palliative care on outcomes of hospitalized patients. Six center study; site PI. Goal: assess the impact of palliative care consultation on health and economic outcomes of hospitalized sick inpatients at 6 major hospitals. Role: Site PI. 10% effort and salary.
9.32.3 JEHT Foundation, New York, New York. Continuation grant for CAPC Palliative Care Leadership Center, $375,000/3 years (to match other program funding.)
9.32.4 Robert Wood Johnson/Center to Advance Palliative Care National Center of Excellence for Palliative Care Education, 7/1/03-6/31/06. $750,000. 20% effort and salary.
9.32.5 American Cancer Society. Targeted Cost-Effectiveness Assessments in Cancer. PI Hillner BE. 01/01/04 to 12/31/07, 2.5% effort/salary, $143,125
9.32.6 Commonwealth of Virginia. Virginia Initiative for Palliative Care (VIPC). 11/05-present. $100,000/year. Train Virginia health care professionals in palliative care.
9.32.7 The goal is to provide objective, non-commercial CEA’s for high cost technology, such as monoclonal antibody therapy.
9.32.8 VistaCare Foundation. Randomized trial of nebulized fentanyl vs placebo for dyspnea. PI, Tom Smith. $10,000. 7.1. 03, one year.
9.32.9 American Cancer Society, Targeted Cost effectiveness Assessments in Cancer Treatments. Bruce Hillner, PI; Tom Smith, Investigator, 2.5%, 1.1.04 to 12.31.07.
9.32.10 2002-5 NCI Core Grant for Massey Cancer Center: co-leader, Cancer Control, 10% time and effort Source: NIH/NCI Grant Number: 5 P30 CA16059-20 $586,494 Period of Support: 6/01/02 - 06/01/07
9.32.11 1999-3 Principal Investigator. AA randomized clinical trial to evaluate the effectiveness, cost-effectiveness, and impact on quality of life of implantable narcotic delivery systems vs. best standardized pain control.” Medtronic, Inc. Minneapolis, MN. Medtronics, Inc. Minneapolis, MN. ~20% salary and time.
9.32.12 1999 Principal Investigator, with Dr. Roger Winn, M.D. Anderson Cancer Center, Houston, Texas. Managed Care Organization Survey, for American Society of Clinical Oncology. $6977.
9.32.13 1999 - Hunton Foundation, Richmond, Virginia. $7,000. Education Center for hospice.
9.32.14 1998-9 Principal Investigator, with Bruce E. Hillner. Assessing the quality of cancer care in the United States.” Report to the Institute of Medicine and National Cancer Advisory Board. 25% effort. (Continued consultations)
9.32.15 1998 Principal Investigator. Randomized clinical trial of implantable narcotic delivery systems”. Medtronics, Inc. Minneapolis, MN. $20,000. Design of clinical trial.
9.32.16 1998-1 Principal Investigator. Creation of a Palliative Care Unit to Serve the Medically Under-served”. Jessie Ball DuPont Fund, Jacksonville, Florida, $287,000/3 years.
9.32.17 1998-01 Consultant, Economic evaluation of CALGB 9343, K. A. Schulman, MD, PI, Georgetown University.
9.32.18 1996-8 Principal Investigator: CALGB 9411, Economic Evaluation of filgrastim (G-CSF) versus placebo during remission, induction, and consolidation for Adult Lymphoblastic Leukemia. Contract under negotiation; 10% effort and salary; $108,000. Unrestricted research grant from CALGB Foundation.
9.32.19 1997- Consultant, R-25, PI-Peter Raich, MD, AMC Cancer Center, Denver, CO. The impact of easy to read consent statements on clinical trials”. Eastern Cooperative Oncology Group, North Central Cancer Treatment Group. 2-4 days/year.
9.32.20 1996-7 Consultant. PI-Ian Tannock, MD PhD, Ontario Cancer Institute. Economic analysis of NOV.22 (Phase 3 trial of mitoxantrone plus low dose prednisone versus low dose prednisone for symptomatic hormone-resistant prostate cancer. $1,000/year.